3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Thromboembolism
3
Venous Thrombosis
2
Colorectal Neoplasms
2
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Gastrointestinal
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled